Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 125
Single User License Price INR 8928
Corporate User License Price USD 375
Corporate User License Price INR 26783
Site License Price USD 250
Site License Price INR 17855
Request a Quote

Report Title

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review

Quote Request for License Type
License Type Price  
Single User License USD 125
Site License USD 250
Enterprise Wide License USD 375
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review


Quote Request for License Type
License Type Price  
Single User License USD 125
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review



Executive Summary

MEDITE Cancer Diagnostics Inc (MDIT)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MEDITE Cancer Diagnostics Inc (MEDITE), formerly CytoCore, Inc., specializes in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. Its major devices include ultrasonic decalcification instruments, tissue processing instruments, freezing microtome, cryostats, linear staining systems, staining systems, and cytology screening systems. The company's products find application in processing tissue, cell collection ranging from processing to diagnosis. These devices and consumables are manufactured at is facility in Burgdorf, Germany. The company sells its products through a direct sale force located in Germany, Poland and the US, and also through independent distributors. MEDITE is headquartered in Orlando, Florida, the US.

MEDITE Cancer Diagnostics Inc Key Recent Developments

Nov 15,2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director

Nov 08,2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer

Aug 14,2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results

Jul 27,2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology

May 10,2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

MEDITE Cancer Diagnostics Inc-Key Facts 5

MEDITE Cancer Diagnostics Inc-Key Employees 6

MEDITE Cancer Diagnostics Inc-Key Employee Biographies 7

MEDITE Cancer Diagnostics Inc-Major Products and Services 8

MEDITE Cancer Diagnostics Inc-History 9

MEDITE Cancer Diagnostics Inc-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Company Overview 12

MEDITE Cancer Diagnostics Inc-Business Description 13

MEDITE Cancer Diagnostics Inc-SWOT Analysis 14

SWOT Analysis-Overview 14

MEDITE Cancer Diagnostics Inc-Strengths 14

MEDITE Cancer Diagnostics Inc-Weaknesses 15

MEDITE Cancer Diagnostics Inc-Opportunities 16

MEDITE Cancer Diagnostics Inc-Threats 17

MEDITE Cancer Diagnostics Inc-Key Competitors 18

Section 3-Company Financial Ratios 19

Financial Ratios-Capital Market Ratios 19

Financial Ratios-Annual Ratios 20

Performance Chart 23

Financial Performance 23

Financial Ratios-Interim Ratios 24

Financial Ratios-Ratio Charts 25

Section 4-Company's Lifesciences Financial Deals and Alliances 26

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 27

MEDITE Cancer Diagnostics Inc, Recent Deals Summary 28

Section 5-Company's Recent Developments 29

Nov 15, 2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director 29

Nov 08, 2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer 30

Aug 14, 2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results 31

Jul 27, 2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology 33

May 10, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 34

Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 35

Apr 27, 2017: MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer 36

Mar 07, 2017: MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors 37

Section 6-Appendix 38

Methodology 38

Ratio Definitions 38

About GlobalData 42

Contact Us 42

Disclaimer 42

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

MEDITE Cancer Diagnostics Inc, Performance Chart (2013-2017) 23

MEDITE Cancer Diagnostics Inc, Ratio Charts 25

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 27

List of Tables

MEDITE Cancer Diagnostics Inc, Key Facts 5

MEDITE Cancer Diagnostics Inc, Key Employees 6

MEDITE Cancer Diagnostics Inc, Key Employee Biographies 7

MEDITE Cancer Diagnostics Inc, Major Products and Services 8

MEDITE Cancer Diagnostics Inc, History 9

MEDITE Cancer Diagnostics Inc, Subsidiaries 11

MEDITE Cancer Diagnostics Inc, Key Competitors 18

MEDITE Cancer Diagnostics Inc, Ratios based on current share price 19

MEDITE Cancer Diagnostics Inc, Annual Ratios 20

MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...1) 21

MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...2) 22

MEDITE Cancer Diagnostics Inc, Interim Ratios 24

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26

MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 27

MEDITE Cancer Diagnostics Inc, Recent Deals Summary 28

Currency Codes 38

Capital Market Ratios 38

Equity Ratios 39

Profitability Ratios 39

Cost Ratios 40

Liquidity Ratios 40

Leverage Ratios 41

Efficiency Ratios 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Cytyc Surgical Products

Dako A/S

Leica Biosystems Nussloch Gmbh

Sakura Finetek USA, Inc.

Thermo Fisher Scientific Inc

TriPath Imaging Inc

MEDITE Cancer Diagnostics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand